The partnership between the Michael J. Fox Foundation for Parkinson’s Research (MJFF) and Swiss biotech firm Biognosys marks a significant step in the quest for new treatments for Parkinson’s disease. This collaboration centers on LRRK2, a biomarker that has gained prominence as a target for drug discovery in managing the disease.
Focus on LRRK2 Biomarker
Biognosys, located in Zurich, will collaborate with researchers from MJFF’s LITE project, which is dedicated to developing inhibitors targeting LRRK2. The goal is to create quantitative biomarker assays that can facilitate both the development of new therapies and the identification of suitable patients for LRRK2-targeted treatments.
LRRK2 is increasingly recognized as a vital target in Parkinson’s research, with numerous drugs currently in development aimed at mitigating the excessive activity of LRRK2 associated with the disease. However, the absence of effective assays for this biomarker has hindered progress in the field.
Current State of LRRK2 Inhibitors
The most advanced LRRK2 inhibitor is DNL151, a small-molecule candidate from Denali Therapeutics, which is currently in mid-stage clinical development. The phase 2b LUMA trial, which involves collaboration with Biogen, is set to provide results in the coming months. This trial targets early-stage Parkinson’s patients, while another ongoing phase 2a study focuses on individuals with LRRK2 mutations.
In 2020, Biogen invested in Denali’s LRRK2 program in a deal worth over $2.1 billion. However, in 2023, Biogen halted a phase 3 trial named LIGHTHOUSE involving LRRK2-positive patients, opting instead to modify the LUMA trial to include those without the mutations. This decision was attributed to the lengthy timeline of the LIGHTHOUSE study rather than concerns regarding the safety or efficacy of the treatment.
Competitive Landscape in LRRK2 Research
Several other companies are also pursuing LRRK2-focused therapies. Neuron23, based in South San Francisco, recently secured $96.5 million to support its phase 2 NEULARK trial for the NEU-411 candidate, targeting early-stage Parkinson’s patients exhibiting elevated LRRK2 activity. Genetic testing will play a crucial role in identifying eligible participants for this trial, with results anticipated in 2027.
Oncodesign Precision Medicines, situated in Dijon, France, has received nearly $7 million from MJFF to conduct a phase 1b trial of OPM-201, a drug previously partnered with Servier. This therapy targets patients with a specific genetic variant of LRRK2 linked to familial Parkinson’s and is expected to commence next year following a successful phase 1a trial.
Boston-based start-up Brenig Therapeutics has also made strides, recently presenting interim data from an ongoing phase 1 clinical trial of BT-267, which is being tested in healthy volunteers.
The Importance of Reliable Biomarkers
Oliver Rinner, senior vice president at Biognosys, emphasizes that successful clinical development relies not only on innovative therapeutic strategies but also on dependable tools for measuring the biological effects of these therapies. The collaboration aims to leverage Biognosys’ expertise in quantitative proteomics alongside MJFF’s LITE framework to accelerate the identification and development of meaningful biomarkers for Parkinson’s.
The Broader Context of Parkinson’s Research
The landscape of Parkinson’s research is evolving, with a shift towards biologically defined frameworks that utilize molecular biomarkers. This trend enhances the precision of treatment strategies and may lead to more effective interventions.
As the focus on LRRK2 continues to grow, the comprehensive understanding of its role in Parkinson’s disease will likely pave the way for breakthrough therapies. The efforts of MJFF and Biognosys represent a significant advancement in this ongoing endeavor.
In conclusion, the partnership between the Michael J. Fox Foundation and Biognosys signifies a promising development in the search for effective Parkinson’s therapies. By focusing on LRRK2 and the creation of reliable biomarkers, this collaboration has the potential to transform the landscape of Parkinson’s research and treatment.
- Collaboration targets LRRK2, a promising biomarker for Parkinson’s.
- Multiple companies are advancing LRRK2 inhibitors, enhancing competition.
- Reliable biomarkers are essential for effective drug development and patient identification.
Read more → pharmaphorum.com